ES2661944T3 - Formas cristalinas de maltol férrico - Google Patents
Formas cristalinas de maltol férrico Download PDFInfo
- Publication number
- ES2661944T3 ES2661944T3 ES15784705.4T ES15784705T ES2661944T3 ES 2661944 T3 ES2661944 T3 ES 2661944T3 ES 15784705 T ES15784705 T ES 15784705T ES 2661944 T3 ES2661944 T3 ES 2661944T3
- Authority
- ES
- Spain
- Prior art keywords
- polymorph
- degrees
- approximately
- powder
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 title claims description 42
- 239000013078 crystal Substances 0.000 title claims description 29
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 title claims description 26
- 229940043353 maltol Drugs 0.000 title claims description 25
- AHPWLYJHTFAWKI-UHFFFAOYSA-K iron(3+);2-methyl-4-oxopyran-3-olate Chemical compound [Fe+3].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] AHPWLYJHTFAWKI-UHFFFAOYSA-K 0.000 claims abstract description 68
- 229950008006 ferric maltol Drugs 0.000 claims abstract description 66
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 62
- 239000000203 mixture Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 45
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 29
- 230000008569 process Effects 0.000 claims description 28
- 208000007502 anemia Diseases 0.000 claims description 24
- 206010022971 Iron Deficiencies Diseases 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 229960002413 ferric citrate Drugs 0.000 claims description 16
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 229910052742 iron Inorganic materials 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 13
- -1 maltol anions Chemical class 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 19
- 238000003756 stirring Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000002425 crystallisation Methods 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000009331 sowing Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000001069 Raman spectroscopy Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005498 polishing Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- QQTUBEKQMMRXHC-UHFFFAOYSA-N 3-hydroxypyran-2-one;iron Chemical class [Fe].OC1=CC=COC1=O QQTUBEKQMMRXHC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002050 diffraction method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BSPCSKHALVHRSR-UHFFFAOYSA-N 2-chlorobutane Chemical compound CCC(C)Cl BSPCSKHALVHRSR-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007519 Plummer-Vinson syndrome Diseases 0.000 description 2
- 206010040664 Sideropenic dysphagia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000007106 menorrhagia Diseases 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- OXXDGKNPRNPMLS-UHFFFAOYSA-N 2-Hydroxy-3-methyl-4H-pyran-4-one Natural products CC1=C(O)OC=CC1=O OXXDGKNPRNPMLS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1419174.6A GB2531742B (en) | 2014-10-28 | 2014-10-28 | Polymorphs of ferric maltol |
| GB201419174 | 2014-10-28 | ||
| PCT/EP2015/074653 WO2016066555A1 (en) | 2014-10-28 | 2015-10-23 | Crystalline forms of ferric maltol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2661944T3 true ES2661944T3 (es) | 2018-04-04 |
Family
ID=52103522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15784705.4T Active ES2661944T3 (es) | 2014-10-28 | 2015-10-23 | Formas cristalinas de maltol férrico |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9802973B2 (enExample) |
| EP (1) | EP3160951B1 (enExample) |
| JP (2) | JP6404358B2 (enExample) |
| KR (1) | KR102576930B1 (enExample) |
| CN (1) | CN107001310B (enExample) |
| AU (1) | AU2015340825B2 (enExample) |
| CA (1) | CA2944210C (enExample) |
| CL (1) | CL2017001030A1 (enExample) |
| EA (1) | EA033323B1 (enExample) |
| ES (1) | ES2661944T3 (enExample) |
| GB (1) | GB2531742B (enExample) |
| IL (1) | IL251863A0 (enExample) |
| MX (1) | MX370730B (enExample) |
| PL (1) | PL3160951T3 (enExample) |
| SA (1) | SA517381406B1 (enExample) |
| SG (1) | SG11201702639RA (enExample) |
| WO (1) | WO2016066555A1 (enExample) |
| ZA (1) | ZA201702136B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531742B (en) | 2014-10-28 | 2016-10-05 | Iron Therapeutics Holdings Ag | Polymorphs of ferric maltol |
| CN112574158B (zh) * | 2020-12-29 | 2022-08-02 | 南京百泽医药科技有限公司 | 一种麦芽酚铁晶型ii及其制备方法 |
| IT202100018578A1 (it) | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
| AU2022349859A1 (en) * | 2021-09-21 | 2024-05-02 | Apicore Pharmaceuticals Private Limited | An improved process for the preparation of ferric maltol |
| CN119638662B (zh) * | 2024-12-09 | 2025-11-14 | 金陵药业股份有限公司 | 一种麦芽酚铁-草酸共晶及其制备方法 |
| CN119638661B (zh) * | 2024-12-09 | 2025-11-14 | 金陵药业股份有限公司 | 一种麦芽酚铁-槲皮素共晶及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE37534E1 (en) | 1982-10-22 | 2002-01-29 | Btg International Limited | Pharmaceutical compositions |
| EP0107458B1 (en) | 1982-10-22 | 1987-07-29 | National Research Development Corporation | Pharmaceutical compositions |
| GB8410290D0 (en) * | 1984-04-19 | 1984-05-31 | Callingham B A | Pharmaceutical compositions |
| GB0211500D0 (en) * | 2002-05-18 | 2002-06-26 | Vitra Pharmaceuticals Ltd | Method of forming iron hydroxypyrone compounds |
| GB201101370D0 (en) * | 2011-01-27 | 2011-03-09 | Iron Therapeutics Holdings Ag | Process |
| WO2014165607A2 (en) * | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| GB2531742B (en) | 2014-10-28 | 2016-10-05 | Iron Therapeutics Holdings Ag | Polymorphs of ferric maltol |
-
2014
- 2014-10-28 GB GB1419174.6A patent/GB2531742B/en active Active
-
2015
- 2015-10-23 SG SG11201702639RA patent/SG11201702639RA/en unknown
- 2015-10-23 US US15/039,943 patent/US9802973B2/en active Active
- 2015-10-23 ES ES15784705.4T patent/ES2661944T3/es active Active
- 2015-10-23 JP JP2016551318A patent/JP6404358B2/ja active Active
- 2015-10-23 MX MX2017005413A patent/MX370730B/es active IP Right Grant
- 2015-10-23 AU AU2015340825A patent/AU2015340825B2/en active Active
- 2015-10-23 CA CA2944210A patent/CA2944210C/en active Active
- 2015-10-23 EA EA201790667A patent/EA033323B1/ru not_active IP Right Cessation
- 2015-10-23 KR KR1020167024732A patent/KR102576930B1/ko active Active
- 2015-10-23 EP EP15784705.4A patent/EP3160951B1/en active Active
- 2015-10-23 PL PL15784705T patent/PL3160951T3/pl unknown
- 2015-10-23 CN CN201580052331.2A patent/CN107001310B/zh active Active
- 2015-10-23 WO PCT/EP2015/074653 patent/WO2016066555A1/en not_active Ceased
-
2017
- 2017-03-27 ZA ZA2017/02136A patent/ZA201702136B/en unknown
- 2017-04-23 IL IL251863A patent/IL251863A0/en unknown
- 2017-04-25 SA SA517381406A patent/SA517381406B1/ar unknown
- 2017-04-26 CL CL2017001030A patent/CL2017001030A1/es unknown
-
2018
- 2018-09-11 JP JP2018169541A patent/JP6678711B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017001030A1 (es) | 2018-01-19 |
| EP3160951B1 (en) | 2017-12-06 |
| JP6404358B2 (ja) | 2018-10-10 |
| KR102576930B1 (ko) | 2023-09-12 |
| AU2015340825B2 (en) | 2016-11-24 |
| IL251863A0 (en) | 2017-06-29 |
| KR20170071446A (ko) | 2017-06-23 |
| GB201419174D0 (en) | 2014-12-10 |
| SA517381406B1 (ar) | 2021-03-15 |
| CA2944210A1 (en) | 2016-05-06 |
| CN107001310A (zh) | 2017-08-01 |
| CA2944210C (en) | 2017-06-20 |
| ZA201702136B (en) | 2018-11-28 |
| WO2016066555A1 (en) | 2016-05-06 |
| US9802973B2 (en) | 2017-10-31 |
| CN107001310B (zh) | 2020-05-22 |
| JP2018197268A (ja) | 2018-12-13 |
| BR112017008903A2 (pt) | 2017-12-19 |
| JP6678711B2 (ja) | 2020-04-08 |
| EA201790667A1 (ru) | 2017-08-31 |
| PL3160951T3 (pl) | 2018-07-31 |
| JP2017535510A (ja) | 2017-11-30 |
| GB2531742A (en) | 2016-05-04 |
| AU2015340825A1 (en) | 2016-08-25 |
| MX370730B (es) | 2019-12-20 |
| MX2017005413A (es) | 2017-10-04 |
| EA033323B1 (ru) | 2019-09-30 |
| EP3160951A1 (en) | 2017-05-03 |
| GB2531742B (en) | 2016-10-05 |
| US20170260222A1 (en) | 2017-09-14 |
| SG11201702639RA (en) | 2017-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2661944T3 (es) | Formas cristalinas de maltol férrico | |
| ES2998139T3 (en) | 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators | |
| JP6206689B2 (ja) | ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉを含有する医薬製剤 | |
| ES2880999T3 (es) | Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas | |
| JP5323476B2 (ja) | ヌクレオチド類縁体プロドラッグおよびその製剤 | |
| JP2919867B2 (ja) | 抗腫瘍剤 | |
| AU2018263965B2 (en) | Manufacture of trans-(tetrachlorobis(1H-indazole)ruthenate (III)) and compositions thereof | |
| JPH0515713B2 (enExample) | ||
| JP2000319290A (ja) | 新規の白金（ｉｖ）錯体及びその製造方法 | |
| KR100339115B1 (ko) | 결정성3-(4-헥실옥시-1,2,5-티아디아졸-3-일)-1,2,5,6-테트라하이드로-1-메틸피리딘(+)l-하이드로겐타르트레이트,이의제조방법및이를포함하는약제학적조성물 | |
| JP2022547208A (ja) | ニコチニルアルコールエーテル誘導体のマレイン酸塩、その結晶形、及びその使用 | |
| WO2022233310A1 (zh) | 丹酚酸a盐水合物、其制备方法及用途 | |
| WO2022228363A1 (zh) | 一种组合物的医药用途 | |
| JPS6310685B2 (enExample) | ||
| CN119235877B (zh) | 一种钌(iii)酸盐的组合物及其应用 | |
| BR112017008903B1 (pt) | Formas cristalinas de maltol férrico | |
| HK1233619A1 (en) | Crystalline forms of ferric maltol | |
| HK1233619B (en) | Crystalline forms of ferric maltol | |
| WO2016010305A1 (ko) | 테노포비어 디소프록실의 신규염 | |
| JPWO2002088147A1 (ja) | セフェム化合物の硫酸塩 | |
| HK40060534A (en) | Use of aminothiol compounds as cerebral nerve or heart protective agent | |
| JPH10298197A (ja) | 置換ベンズアミド誘導体 | |
| KR20110013659A (ko) | 아데포비어 디피복실의 신규한 염 |